- Main
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
- Habtehyimer, Feben;
- Zhu, Xianming;
- Redd, Andrew;
- Gebo, Kelly;
- Abraham, Alison;
- Patel, Eshan;
- Laeyendecker, Oliver;
- Gniadek, Thomas;
- Fernandez, Reinaldo;
- Baker, Owen;
- Ram, Malathi;
- Currier, Judith;
- Fukuta, Yuriko;
- Gerber, Jonathan;
- Heath, Sonya;
- Meisenberg, Barry;
- Huaman, Moises;
- Levine, Adam;
- Shenoy, Aarthi;
- Anjan, Shweta;
- Blair, Janis;
- Cruser, Daniel;
- Hammitt, Laura;
- Kassaye, Seble;
- Mosnaim, Giselle;
- Patel, Bela;
- Paxton, James;
- Raval, Jay;
- Sutcliffe, Catherine;
- Abinante, Matthew;
- Oei, Kevin;
- Cluzet, Valerie;
- Cordisco, Marie;
- Greenblatt, Benjamin;
- Rausch, William;
- Shade, David;
- Gawad, Amy;
- Klein, Sabra;
- Pekosz, Andrew;
- Shoham, Shmuel;
- Casadevall, Arturo;
- Bloch, Evan;
- Hanley, Daniel;
- Tobian, Aaron;
- Sullivan, David;
- Forthal, Donald;
- Cachay, Edward
Published Web Location
https://doi.org/10.1128/spectrum.03286-23Abstract
This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.